August 8, 2019
Stemline Therapeutics (STML) proposes 5 M share offering
April 8, 2019
Histogenics (HSGX) reverse mergers with Ocugen, Inc.
February 26, 2019
Ultragenyx Pharmaceutical (RARE) prices a 5.072 M share offering at $60.00
February 26, 2019
Sage Therapeutics (SAGE) prices 3.33 M share offering at $150.00
January 16, 2019
Stemline Therapeutics (STML) priced an 8.88 M share offering at $9.00 per share
January 15, 2019
Alnylam Pharmaceuticals (ALNY) priced 5 M share offering at $77.50
December 7, 2018
Global Blood Therapeutics (GBT) Prices a $150 M offering at $44.00 per share
October 26, 2018
Neuralstem (CUR) $2.1 M is executing a $2.1 M or 3 M share RDO priced at $0.70
October 14, 2018
Verastem Oncology (VSTM) priced a $150 M offering of 5% Convertible Senior Notes in a registered direct offering
October 10, 2018
Audentes Therapeutics (BOLD) proposed a 5.2 M share offering with a 780 K share overallotment priced at $29.00
September 21, 2018
Fate Therapeutics (FATE) priced their 9,250,260 share offering at $13.50 for an aggregate of approximately $125 million
September 20, 2018
CRISPR Therapeutics (CRSP) prices 4.210526 M shares at $47.50, a $200 M offering with a $30 M underwriting option
August 8, 2018
REGENXBIO (RGNX) proposes a $175 M offering
July 25, 2018
bluebird bio (BLUE) prices 3.348 M share offering at $162.50
June 14, 2018
Verastem Oncology (VSTM) a registered stock sale
May 31, 2018
Vericel (VCEL) proposes 5 M share $65 M offering at $13.00
May 16, 2018
Cellectis SA (CLLS) subsidiary Calyxt (CLXT) proposes offering
May 16, 2018
Cesca Therapeutics (KOOL) prices 9.16 M or $5.5 M offering at $0.60 - SELL
May 16, 2018
Verastem Oncology (VSTM) proposes $35 M offering priced at $4.50 - SELL
May 9, 2018
AxoGen (AXGN) now proposes a 3 M share offering priced at $41.00 - SELL
May 2, 2018
uniQure N.V. (QURE) proposes 4.5 M share offering priced at $28.50
April 26, 2018
Sangamo Therapeutics (SGMO) prices $200 M offering at $16.25 - SELL
April 16, 2018
Bellicum Pharmaceuticals (BLCM) prices 7 M share offering at $7.50
April 9, 2018
Cesca Therapeutics (KOOL) proposes a $10 M unit and attached warrant offering in new prospectus
April 4, 2018
Cellectis (CLLS) prices follow-on $175 M ADS offering
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors